Have any questions? 706-721-6582 or cts@augusta.edu
- A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY
Clinical Trial
A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY
Healthy, pregnant women between the ages of 18 and 49 may be eligible to participate in a vaccine study to prevent respiratory syncytial virus (RSV). Participants (monthers) will be followed until approximately 6 months after delivery. Infants will be followed for 1-2 years after birth.
Eligibility Criteria
- 1. Healthy, pregnant females between the age of 18-49 years of age at enrollment 2. Willing to give informed consent for her infant to participate in the study.
RESEARCH. INNOVATION. DISCOVERY.